RxDoctor Payments DataLook up a doctor →

Alejandro Aldana, MD

Interventional Cardiology · Birmingham, ALNPI 1295739274

Payments from drug & device makers

$13,190in general payments, 2019–2025

Across 306 payments — averaging $43.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$5K
  • Inari Medical, Inc.$2K
  • Novartis$656
  • Stryker$567
  • Johnson & Johnson$539
  • Medtronic$500
  • plus $4K from 47 others

What the payments were for

  • Travel & lodging$4,20432%
  • Food & beverage$8,97368%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,190 in reported general payments places this provider in the 55th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$155,164
Medicare patients
519
Services billed
1,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban505$495,340
XareltoRivaroxaban94$95,697
JardianceEmpagliflozin61$49,443
EntrestoSacubitril/Valsartan32$38,985
FarxigaDapagliflozin Propanediol34$33,816
MultaqDronedarone Hcl16$18,944
Metoprolol Succinate1,028$15,219
BrilintaTicagrelor18$13,144
Repatha SureclickEvolocumab16$8,760
Atorvastatin Calcium547$8,287
Rosuvastatin Calcium382$7,294
Repatha SyringeEvolocumab12$6,275
Losartan Potassium486$6,008
Diltiazem 24hr Er (Cd)Diltiazem Hcl104$5,350
Flecainide Acetate80$4,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$384$495,340505 claims
Johnson & JohnsonXarelto$539$95,69794 claims
Boehringer IngelheimJardiance$141$49,44361 claims
AstraZenecaFarxiga, Brilinta$188$46,95952 claims
NovartisEntresto$656$38,98532 claims
Sanofi-aventis U.S. LLCMultaq$197$18,94416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →